A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
ConditionHidradenitis Suppurativa (HS)
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBluefin Biomedicine, Inc.
About this trial
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
Eligibility criteria
Qualifiers
Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.
Have moderate to severe disease not well controlled by systemic antibiotic treatment.
Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.
Disqualifiers
Have certain infections or other immune conditions.
Recently used medications that could interfere with the study.
Are pregnant or breastfeeding.
Trial design
Treatments tested in this trial
- BFB759
- Placebo for BFB759
Treatment groups
210 Participants
are divided into 3 treatment groupsLocations
58Bulgaria
Medical Center Medconsult Burgas EOOD Burgas Bulgaria
Medical Center Medconsult Pleven-Lovech Branch Lovech Bulgaria
Medical Center Medconsult Pleven OOD Pleven Bulgaria
Medical Center Etika Ambulatory For Specialized Outpatient Medical Care OOD Plovdiv Bulgaria
Sponsors and collaborators
Bluefin Biomedicine, Inc.
Lead sponsor
Source ClinicalTrials.gov